Avacta Group Share News (AVCT)

Avacta Group Information

Buy AVCT Shares
Add AVCT to Watchlist
Add AVCT to Alert

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 45.50

Bid: 45.00

Ask: 46.00

Change: -1.00 (-2.15%)

Spread: 1.00 (2.222%)

Open: 46.50

High: 45.50

Low: 45.00

Prev. Close: 46.50

Last checked at -

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Tue, 20th Apr 2021 12:17

Avacta Group PLC - Yorkshire-based drug and medical equipment maker - Lateral flow test for Covid-19 is shown to have 98% sensitivity in clinical study. 20-minute AffiDX test correctly identified 96 out of 98 positive samples of virus and 101 out of 102 negative samples. Test effective on a range of viral loads. Company will file for a CE mark in May and start commercial roll-out in coming months.

Current stock price: 261.69 pence, up 12% on Tuesday

Year-to-date change: more than doubled from 114p on December 31

By Ivan Edwards; ivanedwards@alliancenews.com

More News

15 Dec 2021 08:24

Avacta antigen lateral flow test shown to detect Omicron

(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

29 Nov 2021 11:07

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

29 Nov 2021 10:38

FDA gives Avacta the go-ahead for US chemotherapy trials

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.

2 Nov 2021 11:25

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

2 Nov 2021 10:21

Avacta suspends UK Covid test sales ahead of new approval

(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.

30 Sep 2021 11:14

Avacta hails "transformative" first half despite widening loss

30 Sep 2021 09:27

Avacta losses widen as development spend increases

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.

29 Sep 2021 10:32

Avacta sees pre-clinical development milestone in LG Chem partnership

29 Sep 2021 09:26

Avacta gets undisclosed milestone payment from LG Chem

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Wednesday that a preclinical development milestone has been achieved in its multi-target therapeutics partnership with South Korea's LG Chem Life Sciences, triggering an undisclosed milestone payment.

23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

2 Sep 2021 11:50

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

18 Aug 2021 14:26

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

11 Aug 2021 11:29

Avacta doses first patient in chemotherapy medication trial

11 Aug 2021 10:00

First patient dosed in Avacta's 'AVA6000' trial

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.

4 Aug 2021 17:53

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Avacta antigen lateral flow test shown to detect Omicron

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

FDA gives Avacta the go-ahead for US chemotherapy trials

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Avacta suspends UK Covid test sales ahead of new approval

Avacta hails "transformative" first half despite widening loss

Avacta losses widen as development spend increases

Avacta sees pre-clinical development milestone in LG Chem partnership

Avacta gets undisclosed milestone payment from LG Chem

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

Avacta doses first patient in chemotherapy medication trial

First patient dosed in Avacta's 'AVA6000' trial

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Login to your account

Quickpicks are a member only feature

Login to your account